Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O60524

UPID:
NEMF_HUMAN

ALTERNATIVE NAMES:
Antigen NY-CO-1; Nuclear export mediator factor; Serologically defined colon cancer antigen 1

ALTERNATIVE UPACC:
O60524; A0JLQ3; B3KSK1; B4DDL3; B4DHA9; B4E3F3; Q32Q66; Q8WW70; Q9NWG1

BACKGROUND:
The Ribosome Quality Control Complex Subunit NEMF, known alternatively as Nuclear Export Mediator Factor, is integral to the RQC pathway. It ensures the fidelity of protein synthesis by mediating the degradation of stalled nascent polypeptide chains, a process critical for maintaining cellular health and preventing the toxic accumulation of incomplete proteins.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in preventing the accumulation of toxic nascent polypeptide chains, Ribosome Quality Control Complex Subunit NEMF represents a promising target for therapeutic intervention in diseases like Intellectual Developmental Disorder with Speech Delay and Axonal Peripheral Neuropathy. Exploring its functions further could unveil novel therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.